Results 11 to 20 of about 91,755 (270)

Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab

open access: yesActa Oncologica
Background and purpose: This study aims to evaluate neutrophil-to-eosinophil ratio (NER) as a prognostic and/or predictive biomarker in metastatic clear cell renal cell carcinoma (m-ccRCC) treated with nivolumab or ipilimumab/nivolumab.
Yana Beulque   +15 more
doaj   +5 more sources

Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab

open access: yesJournal for ImmunoTherapy of Cancer
Background The combination of ipilimumab and nivolumab is a highly effective treatment for metastatic cutaneous melanoma. However, immune-related adverse events (irAEs) are common, often necessitating treatment interruption and the use of ...
David Liu   +11 more
doaj   +2 more sources

Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma

open access: yesRespiratory Medicine Case Reports, 2020
Malignant pleural mesothelioma (MPM) is a rare and highly aggressive tumor. Nivolumab showed durable antitumor effect in patients with recurrent MPM and was approved for those patients in Japan in 2018.
Jun Sakakibara-Konishi   +9 more
doaj   +2 more sources

Model-based clinical pharmacology profiling of subcutaneous nivolumab in renal cell carcinoma: Bridging to alternative dosing regimens and indications. [PDF]

open access: yesClin Pharmacol Ther
A novel model‐informed drug development (MIDD) approach was employed to derive the coprimary endpoints (time‐averaged serum concentration over 28 days [Cavgd28] and minimum serum concentration at steady state [Cminss]) of the phase III CheckMate 67T study (NCT04810078).
Zhao Y   +5 more
europepmc   +2 more sources

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

open access: yes, 2022
BACKGROUND Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion.
Abaskharoun, Mena   +25 more
core   +3 more sources

Nivolumab and Olaparib [PDF]

open access: yesHospital Pharmacy, 2015
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Dominic A, Solimando, J Aubrey, Waddell
openaire   +2 more sources

Nivolumab-Related Dry Mouth and Dry Eye: Cross-Sectional Study

open access: yes, 2021
To evaluate ICIs related dry eye and dry mouth in nivolumab therapy, 24 patients receiving nivolumab (group 1), 30 patients in remission without treatment for 6 months (group 2), 30 healthy participants (group 3) were cross-sectionally examined. Schirmer’
Kerem Poyraz (11466373)   +7 more
core   +1 more source

Focus on Nivolumab in NSCLC [PDF]

open access: yesFrontiers in Medicine, 2016
Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issues.
Cortinovis D. L.   +4 more
openaire   +3 more sources

Nivolumab in melanoma [PDF]

open access: yesExpert Review of Anticancer Therapy, 2016
The treatment of melanoma is evolving rapidly over the past few years. Areas covered: We conducted a comprehensive review of the literature on the role of nivolumab in melanoma Expert commentary: Nivolumab is approved by FDA and EMA for the treatment of patients with metastatic melanoma.
openaire   +2 more sources

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [PDF]

open access: yes, 2016
BACKGROUND: Treatments for small-cell lung cancer (SCLC) after failure of platinum-based chemotherapy are limited. We assessed safety and activity of nivolumab and nivolumab plus ipilimumab in patients with SCLC who progressed after one or more prior ...
Taylor, Matthew   +72 more
core   +1 more source

Home - About - Disclaimer - Privacy